INS and metabolic dysfunction-associated steatohepatitis: Some excitement was generated when initial results from pre-clinical and early-clinical outcomes were reported showing improved hepatic function with the use of cenicriviroc, a dual CCR2/CCR5 chemokine receptor antagonist in hepatic pathology, however these reactions were tempered when the agent was unable to improve insulin sensitivity in patients with NASH (138).